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Accepted 10 March 2017Background: Thrombotic risk constitutes a major complication of atrial fibrillation (AF). Platelets andmicroparti-
cles (MPs) are important for hemostasis and thrombosis, however their participation during AF is not well
known. The aim of this study was to characterize platelet function andMPs procoagulant and fibrinolytic activity
in AF patients and to determine the effects of an acute-AF episode.
Methods: Blood was collected from paroxysmal (21) and persistent (16) AF patients referred for AF catheter ab-
lation. Ten patients in sinus rhythm for 10 days were induced in AF allowing comparisons of left atrium samples
before and after induction. Platelet aggregationwith ADP, TRAP, collagen, and ristocetinwas studied. Platelet sur-
face expression of PAR-1, αIIbβ3, GPIb and P-selectin were evaluated by flow cytometry, and MPs-associated
procoagulant and fibrinolytic activity levels were determined by functional assays.
Results:A specific reduction in platelet aggregation to TRAP, activating the thrombin receptor PAR-1,was found in
all AF patients. No differences in platelet receptor expressionwere found. Yet, after acute-induced AF, the platelet
response was improved. Furthermore, a significant decrease of left atrium tissue factor-dependent procoagulant
activity of MPs was observed.
Conclusion: Acute episodes of AF results in a decrease in MPs-associated tissue factor activity, possibly corre-
sponding to consumption, which in turn favors coagulation and the local production of thrombin. A decreased
platelet basal aggregation to TRAP may result from PAR1 desensitization, whereas the improved response after
an induced episode of AF suggests activation of coagulation and PAR1 re-sensitization.
© 2017 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Atrial fibrillation (AF) is the most common cardiac arrhythmia,
occurring in 1–2% of the world's population with risk increasing
with age [1]. Radiofrequency ablation emerged in the late 1990's,
and is now an important approach in treating AF decreasing the bur-
den of the arrhythmia [2,3]. One of the main complications of parox-
ysmal or permanent forms of AF is increased risk of a stroke; with
20% of stroke patients being related to AF [1,4]. Vitamin-K antagonist
(VKA), and more recently direct oral anticoagulants (DOAC) are a
cornerstone of anti-thrombotic treatments for patients with AF.
Nevertheless, even with these drugs, stroke may still occur in pa-
tients presenting AF.e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Baseline characteristics of AF patients.
Paroxysmal AF
(n= 21)
Persistent AF
(n= 16)
p value
Age 60 ± 2.6 59 ± 2.0 p= 0.63
Men/women 14:7 14:2 p= 0.25
BMI 26.3 ± 1.0 26.6 ± 1.0 p= 0.84
CHA2DS2-VASc Score 1.3 ± 0.2 0.9 ± 0.3 p= 0.44
Duration of AF (years) 6 ± 1.2 5.8 ± 1.1 p= 0.90
Comorbidities
Hypertension (%) 28.6 18.8 p= 0.70
Diabetes mellitus (%) 4.8 0 p= 1.00
Stroke/transient ischemic
attack (%)
9.5 0 p= 0.50
Treatment
Class I antiarrhythmics (%) 57.1 25 p= 0.05
Class II antiarrhythmics (%) 14.3 43.8 p= 0.07
Class III antiarrhythmics (%) 33.3 81.3 ⁎⁎p= 0.01⁎⁎
VKA (%) 47.6 25.0 p= 0.19
DOAC (%) 42.9 75.0 p= 0.09
Echocardiographic parameters
LA surface (cm2) 19.6 ± 0.9 24.5 ± 2.9 p= 0.12
LVEF (%) 62.1 ± 1.4 58.3 ± 4.5 p= 0.92
Value are mean ± SEM or %. ⁎⁎p ≤ 0.01. AF = atrial fibrillation; BMI = body mass index;
CHA2DS2-VASc Score = congestive heart failure, hypertension, age ≥ 75 years, diabetes,
stroke, vascular disease, age 65 to 75 years, sex category (female); LA = left atrium;
LVEF = left ventricular ejection fraction, DOAC= direct oral anti-coagulant; VKA= vita-
min K antagonist.
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anisms, including hemodynamic dysfunction and modifications of he-
mostatic parameters. Hemodynamic problems are most often due to
modifications of bloodflow in the left atrium(with the loss of atrial con-
traction and atrio-ventricular synchronization), atrial tissue remodeling
and inflammation processes [5]. Among hemostatic parameters, plate-
lets are important players. They are small, anucleate blood cells that
upon endothelial damage form a hemostatic plug, helping to prevent
blood loss at sites of vascular injury. They adhere to sites of vascular in-
jury through interactions between glycoprotein (GP) receptors with
von Willebrand factor (VWF) and collagen, present in the exposed
subendothelial matrix. Platelets then aggregate and secrete biologically
active substances, proteins and newly synthesized active metabolites
[6]. They form a procoagulant surface enhancing the coagulation cas-
cade ending in the formation and stabilization of the hemostatic plug fa-
voring thrombin generation and fibrin formation. Secreted proteins are
capable of influencing processes such as angiogenesis, inflammation
and the immune response. During activation or apoptotic processes,
large numbers of small vesicles called microvesicles or microparticles
(MPs) may form and be shed from the surface of the platelets, leuko-
cytes and vascular cells [7]. MPs are important in thrombosis, inflamma-
tion and vascular reactivity. They behave as biological drones playing a
key role in the fine-tuning of vascular homeostasis. Beyond their well-
described procoagulant properties, accumulating data has shown that
specific endothelial cell or leukocyte-derived MPs bind plasminogen
and vectorize plasminogen activators, leading to an efficient plasmin
generation and matrix metalloproteinases activation [8]. Studies with
AF patients did not show increased plasmin activity, but an abnormal fi-
brinolytic balance [9]. If AF is associated with an increased thrombotic
tendency the role of platelets and other changes needs to be established.
We have analyzed in non-valvular AF, the platelet aggregation re-
sponse, expression of selected platelet membrane GPs, and the levels
ofMPs-linked procoagulant and fibrinolytic activities. These parameters
were measured in paroxysmal and persistent AF patients from periph-
eral blood samples and directly from blood in the left atrium during
the ablation procedure. As atrial fibrillation had to be induced in some
patients to map atrial fragmented signals, this procedure allowed us to
examine if the newly identified biomarkers were directly linked to an
acute episode of fibrillation.2. Methods
2.1. Patients
Paroxysmal and persistent AF patients referred for primary AF catheter ablation were
included in this study and baseline characteristics are described in Table 1. Paroxysmal AF
patients (n = 21) were defined as having at least 2 self-converting episodes lasting
b7 days. Persistent AF patients (n = 16) were defined as AF lasting longer than 7 days
[3]. Healthy control subjects (n=11)were from the hospital and research center staff. Ex-
clusion criteriawere active smokers, antiplatelet treatment, history of acute cardiac events
in the preceding 3months, valvular heart diseases, chronic inflammatory diseases, chronic
renal and hepatic disease, and uncontrolled hypertension. In our 37 patient cohort, 24 pa-
tients were administered with 100 mg of ketoprofen (nonsteroidal anti-inflammatory
drugs (NSAIDs)) before the beginning of the procedure and heparin was given after the
trans-septal puncture.
This study was in accordance with the declaration of Helsinki and was approved by
the local institutional review committee (2016-A00603-48). Informed consentwas signed
by the patients and controls.2.2. Blood collection
Blood samples from AF patients were taken during AF ablation procedures, using a
trans-septal approach [3]. Citrated and EDTA blood samples were collected from the fem-
oral vein, and the left atrium immediately after trans-septal puncture and heparin admin-
istration. Among the 37 patients included in the study, a subgroup of patients in sinus
rhythm (n = 10) throughout the 10 days prior to ablation were subjected to induced-
AF by pacing at the coronary sinus catheter (paroxysmal AF n= 5, persistent AF n= 5).
After 20 min of continuous AF, additional blood samples were collected from the left atri-
um (before radiofrequency energy delivery). Peripheral blood samples were collected
from healthy volunteers via the cubital vein.2.3. Platelet function
Blood cell counts were recorded. Platelet-rich plasma (PRP) and platelet-poor plasma
were prepared following the SSC/ISTH recommendations. PRP platelet count lower than
150 × 10^9 l−1 and higher than 600 × 10^9 l−1 were excluded [10]. Platelet aggregation
was assessedusing anAPACT4004 aggregometer (Elitech, Puteaux, France) by light transmis-
sion over 10 min after adding adenosine diphosphate (ADP) 10 μM, ristocetin 1.5 mg/ml
(Elitech, Puteaux, France), Horm collagen 2 μg/ml (Stago, Taverny, France) or thrombin re-
ceptor activating peptide (TRAP-6mer) 10 μM(Bachem, Bubendorf, Switzerland). Percentage
ofmaximal intensity aggregation andmaximal disaggregation after addition of agonistswere
determined from the recordings [9].
2.4. Platelet membrane receptor expression
Expression of αIIbβ3 and GPIb was evaluated by flow cytometry with a FacsCanto I
(BD biosciences, Franklin Lakes, New Jersey, USA) as previously described [11]. For PAR-
1 and P-selectin detection, mouse anti-thrombin receptor antibody PE conjugates (clones
WEDE15 and SPAN12) (Beckman-Coulter, Brea, California, USA) and mouse anti-CD62P-
PE (BD, biosciences, Franklin Lakes, New Jersey, USA)weremixedwith 106 platelets. Neg-
ative controls consisted of the addition of isotype mouse IgG1-PE antibodies (Beckman
Coulter, Brea, California, USA and BD Biosciences, Franklin Lakes, New Jersey, USA). Levels
ofαIIbβ3, GPIb and PAR-1were determined asmean fluorescence intensity (MFI) and the
level of P-selectin expression was determined as a percentage of positive cells compared
to the negative control set at 1%.
2.5. Evaluation of microparticle functions
Platelet free plasma sampleswere prepared following the SSC/ISTH recommendations
[12]. TF-dependent procoagulant activity ofMPswas determinedusing afluorogenic assay
of factor Xa generated by purifiedMPs as described inAgouti et al. [13]. Thefibrinolytic ac-
tivity of MPs was determined using a chromogenic test of plasmin generated by purified
MPs asmodified by BioCytex (separation of plasmaMPsby immuno-magnetic separation)
[14].
2.6. Statistical analysis
Categorical variables were compared using Fisher's exact or Pearson's chi-square test as
deemed appropriate. As normality or equal variance test failed on several continuous vari-
ables and the small size of the study, statistical analysis was performed by non-parametric
tests. To compare the control, paroxysmal and persistent AF groups for platelet function,
membrane receptor expression and MPs, the Kruskall-Wallis test was performed. A Mann-
Whitney test was used to determine the effect of NSAID administration and cardiac rhythm
during blood sampling on maximal aggregation variables. The effect of an acute AF episode
and site samplingonplatelet function,membrane receptor expression andMPswas analyzed
by Wilcoxon test. Statistical significance was established at p b 0.05. All data was analyzed
using GraphPad Prism (version 6.07).
Fig. 1. Platelet aggregation response. Platelet aggregation profiles in response to collagen (2 μg/ml), ADP (10 μM), ristocetin (1.5 mg/ml) and TRAP (10 μM) for control, paroxysmal (Parox
AF) and persistent (Pers AF) AFpatients (a). Composite data representing themeanpercent aggregation intensity of platelets fromperipheral blood for controls (n=11) and from samples
taken from the left atrium for paroxysmal (n=21) and persistent (n=16) AFpatients. Comparison of themaximal aggregation intensity and the residual intensity after disaggregation in
response to TRAP, between control, paroxysmal and persistent AF patients (b), between patients receiving anti-inflammatory drugs or not (c), between blood samples taken in sinus
rhythm and in fibrillation (d). Data are represented as box and whiskers. Box plots display first and third quartiles and horizontal lines display median. Whiskers are represented with
Tukey's method. Symbols represent outliers. ⁎p ≤ 0.05 ⁎⁎⁎p ≤ 0.001. AF = atrial fibrillation, NSAIDs = nonsteroidal anti-inflammatory drugs, SR = sinus rhythm.
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3.1. AF pathology is associated with platelet aggregation abnormalities
For all patients and control subjects, platelet counts (control: 257 ±
19 G/l, paroxysmal: 219 ± 12 G/l, persistent: 237 ± 17 G/l) and mean
platelet volumes (control: 7.8 ± 0.3 μm3, paroxysmal: 7.9 ± 0.2 μm3,
persistent: 7.9 ± 0.2 μm3) were within normal ranges and there was
no significant differences between groups.
Platelet aggregation in patients with paroxysmal or persistent AF
showed a lowermaximal intensity compared to controls for all agonists,
including collagen, ADP, ristocetin and TRAP (Fig. 1a). It was with TRAP
that the difference between platelet responses from paroxysmal AF
compared to persistent AF was highly significant. No significant differ-
ence of platelet aggregation in response to collagen, ADP, ristocetin
and TRAP, between peripheral and left atrium blood samples wasFig. 2. Left atriumplatelet aggregation response after acute-AF episode and expression ofmajor
in the legend to Fig. 1. Data of maximal intensity aggregation and percent disaggregation in resp
patients in sinus rhythm during a period of 10 days and following AF induction. Comparison
persistent (Pers AF) AF patients (e), between left atrium blood samples from patients in sinu
expression between controls, paroxysmal and persistent AF patients (g).observed, suggesting that platelet function in AF patients was globally
affected (Supplementary Fig. A.1).
Statistical comparative analysis between control, paroxysmal and
persistent forms revealed that maximal percentage aggregation induced
by TRAP was significantly lower in paroxysmal AF compared to control
(p b 0.001) and persistent AF (p = 0.02) (Fig. 1b). Furthermore, the
lower maximal intensity of platelet aggregation was associated with a
high reversibility of aggregation in paroxysmal AF patients compared to
control (p b 0.001) (Fig. 1b). The platelet aggregation response to TRAP
agonist in patients was statistically unrelated to NSAID administration
(Fig. 1c) and to cardiac rhythm at the time of blood sampling (Fig. 1d).
3.2. Acute-AF induced increased platelet aggregation
Subsequently, to evaluate whether a short burst of AF influences
platelet functions, we analyzed the immediate effect of 20 min ofplateletmembrane receptors including PAR-1. Data are represented as box andwhiskers as
onse to ADP (a), ristocetin (b), TRAP (c) and collagen (d) in left atriumblood samples from
of αIIbβ3, GPIb and P-selectin expression between controls, paroxysmal (Parox AF) and
s rhythm during 10 days and following AF induction (f). Comparison of PAR-1 epitopes
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in sinus rhythmover at least 10 days. Platelet responses to ADP (Fig. 2a)
and ristocetin (Fig. 2b) were not modified in left atrium blood samples
taken in sinus rhythm and after 20 min of continuous AF. However, in-
duction of acute-AF increased themaximal intensity of platelet aggrega-
tion induced by TRAP (p = 0.02) (Fig. 2c). This increase of platelet
aggregation was associated with a reduced reversibility of aggregation
(p=0.05) (Fig. 2c). An acute-AF episode also increasedmaximal plate-
let aggregation induced by collagen (p=0.03)without any effect on the
reversibility (Fig. 2d).
These results indicated that an acute-AF episode was sufficient to
modify platelet function, in particular, the response to the thrombin an-
alog. Thus AF influences platelet functionality differently in the long and
short term.
3.3. Platelet αIIbβ3, GPIb and expression of P-selectin remain normal
Flow cytometric analysis of the expression of αIIbβ3 and GPIb, the
major platelet receptors involved in platelet aggregation and adhesion
showed normal results in left atrium blood samples (Fig. 2e). P-selectin
is a measure of platelet activation and granule secretion. The percentage
of platelets expressing P-selectin in the left atrium from paroxysmal and
persistent AF patientswas not significantly different to that of the controls
(Fig. 2e). PlateletαIIbβ3, GPIb and P-selectin receptor expressionwas not
significantly different when comparing peripheral blood to that taken
from the left atrium (Supplementary Fig. A.2). Finally, an acute-AF epi-
sode induced in patients in sinus rhythm over 10 days did not generate
anymodification to plateletαIIbβ3, GPIb and P-selectin expression levels
(Fig. 2f).Fig. 3. Assessment of MPs-linked fibrinolytic and TF-dependent procoagulant activities. Data ar
for controls and results for samples taken from the left atrium are presented for patients. Co
controls, paroxysmal (Parox AF) and persistent (Pers AF) AF. Compared levels of fibrinolyt
samples from patients in sinus rhythm during 10 days and following AF induction.⁎p ≤ 0.05,⁎⁎p3.4. Thrombin receptor PAR-1 expression and activation
Because the platelet aggregation response to TRAP was abnormal,
we analyzed the expression of the thrombin receptor PAR-1 by flow cy-
tometry using two different commercial antibodies. The peptide TRAP
mimics a ligand domain of PAR-1 that interacts with the receptor
resulting in activation. A neoepitope becomes exposed after cleavage
of the receptor by thrombin. The WEDE15 antibody reacts with both
cleaved and uncleaved receptors whereas the SPAN12 antibody reacts
exclusively with the uncleaved form. As shown in Fig. 2g, neither
WEDE15 nor SPAN12 binding was modified in AF compared to healthy
volunteers, suggesting that (i) the receptor has not previously been
cleaved by thrombin and (ii) that the abnormal response to TRAP was
not associatedwith a significantmodification of the receptor expression
levels.
3.5. Fibrinolytic and TF-dependent procoagulant activities of MPs in AF
patients
Analysis of MPs by functional assays revealed different behavior be-
tween fibrinolytic and TF-dependent procoagulant MPs-associated activ-
ities. Levels of fibrinolytic activity were consistent between patients and
controls, although a small reductionwas found in paroxysmal AF patients
compared to controls (p=0.01) (Fig. 3a). Levels of procoagulant activity
(of MPs) were lower in both paroxysmal and persistent AF patients
compared to controls (p b 0.01) (Fig. 3b). Similar studies were performed
before and after acute induction of AF. Levels of fibrinolytic activity in the
left atrium showed no difference between AF patients in sinus rhythm
versus 20 min after the onset of AF (Fig. 3c), whereas TF-dependente represented as in the legend to Fig. 1. Results for peripheral blood samples are presented
mpared levels of fibrinolytic (a) and TF-dependent procoagulant (b) functions between
ic (c) and TF-dependent procoagulant (d) functions of MPs between left atrium blood
≤ 0.01.
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20 min of acute-AF (Fig. 3d). The mechanism below these observations
remains to be clarified, a first hypothesis being that TF-dependent
procoagulant MPs are preferentially used locally following tissue mod-
ification induced by AF.
4. Discussion
We have investigated platelet function as well as the procoagulant
and fibrinolytic activity of MPs in patients with persistent and parox-
ysmal non-valvular AF with, for some cases, an analysis of the direct
effect of an acute-AF episode. Initial results showed a significant re-
duction in the platelet aggregation response to TRAP, a synthetic
peptide activating the thrombin receptor PAR-1. Present in both
groups of patients, this decrease was greater for paroxysmal than
for persistent AF, not only locally in atrial blood but also in the pe-
ripheral circulation. Interestingly, an acute episode of induced-AF
improved the platelet response to TRAP, indicating that (i) short AF
episodes are able to directly influence platelet aggregation and (ii)
the decreased response of platelets to TRAP observed for paroxysmal
and permanent AF can be partially reversed. The results showing an
abnormal platelet thrombin receptor response, strongly suggest
prior contact of platelets with thrombin.
Abnormal formation of thrombin during AF has been previously
reported, with the presence of increasedmarkers of thrombin gener-
ation in the circulation such as thrombin-antithrombin complexes
and D-dimer [15,16] but without increased fibrinolytic activity [17,
18]. Thrombin not only has a crucial role for fibrin generation, but
it is also a potent platelet activator. When thrombin is formed, plate-
let PAR-1 and PAR-4 receptors can be cleaved, first activating plate-
lets, leading to a secondary platelet refractory state through
receptor desensitization [19]. To explain the decreased platelet re-
sponse to TRAP for AF patients, one hypothesis is that some of the
PAR-1 receptors were cleaved or missing from the surface. Quantifi-
cation of PAR-1 performed using cleavage-sensitive and insensitive
antibodies showed no significant decrease in platelet surface expres-
sion. However, it cannot be excluded that many of the affected plate-
lets are rapidly removed from the circulation. A recent investigation
of platelet PAR-1 receptors on AF patients receiving dabigatran, a di-
rect thrombin inhibitor that blocks thrombin catalytic activity,
showed an increased expression of PAR-1 after the patients had re-
ceived this treatment [20]. This finding would be in agreement
with a direct action of thrombin on platelets of AF patients.
PAR-1 activation can also result from interactions with proteases
other than thrombin [21]. Plasmin cleaves PAR-1, but for AF patients in-
creased circulating levels of plasmin have not been described [9] and the
stable amount of fibrinolytic activity in MPs after induced-AF in our
study is not in favor of this hypothesis. Metalloproteases (MMP)-1 and
-2 are present in platelets, it was recently demonstrated that MMP-2
stimulates PAR-1 through Gq and G12/13 signaling pathways though
it is insufficient to cause platelet aggregation and only predisposes
platelets to a full responsewith a Gi activating signaling [22].We cannot
exclude a contribution of MMPs for our patients, but trace amounts of
thrombin have already been reported in the circulation in AF [23]. Inter-
action of proteases with PAR-1 initiates receptor cleavage, signaling and
desensitization. Desensitization can be brought about by internalization
of PAR-1 receptors, a process often seen in vascular cells, but limited in
platelets as shown by electron microscopy and immunogold labeling of
platelet sections of thrombin-stimulated platelets [24]. Alternatively,
desensitization can be mediated through an arrestin-dependent path-
way, again reported in nucleated cells but for platelets only reported
for PAR-4 [25,26]. A third way of modulating PAR-1 activation has
been shown for platelets incubated with TRAP peptide and consists of
the desensitization of PAR-1 signaling, including a decrease in Ca2+mo-
bilization, restricted protein kinase C substrate phosphorylation and re-
duced secretion but not associated with a modification of PAR-1expression on platelet surface [27]. Further tests are required to see if
the platelets of patients such as those examined in our study exhibit
this profile.
We provide evidence that, after a short-time of induced-AF,
platelets became more reactive and decreased PAR-1-dependent ag-
gregation was partially corrected. In vitro experiments showed that
PAR-1 desensitized platelets can respond to amounts of a second
thrombin receptor (PAR-4) agonist, suggesting that thrombin can
abrogate rapidly the inhibitory state and that this is sufficient to re-
establish aggregation. Importantly, this also signifies that a partial
refractory state does not protect platelets from a second wave of
thrombin. These results are highly suggestive of: (i) a desensitization
process greater in paroxysmal AF than in the permanent form and
(ii) an equilibrium between platelet activation and desensitization;
whereby activation is elevated relative to desensitization in perma-
nent AF (Supplementary Fig. A.3). Typically, AF evolves from a parox-
ysmal to a persistent form. For paroxysmal AF, restoration to sinus
rhythm can in most cases be achieved by “anatomical” catheter abla-
tion limited to the pulmonary veins. Whereas for the persistent form,
zones of electrical remodeling in the atrium are more diffuse leading
to changes in ion channels, signaling pathways, calcium handling,
and structural changes in the atrial tissue associated with oxidative
stress, inflammation and atrial fibrosis [28]. These observed modifi-
cations during the evolution of AF may explain the increased platelet
response to TRAP observed in permanent AF.
Elevated P-selectin expression was observed for two AF patients but
statistically significant differences were not found between the grouped
AF patients and controls. Small increases in expression of this marker,
commonly used to evaluate platelet activation, have been reported in
AF but the results are still controversial [29]. Willoughby et al. found a
mild increase in platelet activation for blood taken either from the
right or left atrium of patients with AF [30]. However, Choudhury et al.
found low levels of activation in the presence of patient comorbidities
(e.g. diabetes) [31]. Another possibility to explain the absence or low
levels of P-selectin-expressing platelets is rapid removal from the circu-
lation [32]. Platelet P-selectin was shown to be increased after inducing
AF [33] but as measurements were obtained following fixation with
methanol-based solution (CellFix®, BD biosciences), which gives access
to the internal pool of this receptor, these observations cannot be com-
pared to our results.
In our study, levels of MPs-associated, TF dependent activity were
measured in the left atrium of AF patients, using a highly sensitive func-
tional assay that has the capacity of detecting TF activity even in normal
healthy control samples. The most important result that we report are
lower levels of TF-dependent activity in the left atrium observed after
an acute-induced AF episode in comparison with measurements per-
formed under the same conditions before inducing AF. Thismay suggest
that (i) TF-dependent MPs may be captured by the surrounding tissues
and/or incorporated into micro-clots or (ii) that higher levels of inhibi-
tors such as TF pathway inhibitor may be bound to MPs. In previous
studies, levels of PS-expressing MPs were found to be increased in AF
patients [34]. But these studies were performed under basal conditions
and did not evaluate the effect of an induced acute-AF episode. Jesel
et al. have previously shown that levels of TF-dependentMPsmeasured
in both upper cardiac chambers were slightly lower in the left atrium,
here again suggesting a local consumption [35]. We show that MPs-
linked fibrinolytic activity was not modified in patients with AF, but it
would be important to examine these fibrinolytic MPs in the long-
term especially as they have been shown to play a role in fibrosis forma-
tion by TGF-β1 activation [36].
The observed reduced TF-dependent procoagulant activity of as an
increased platelet aggregation after an induced-AF episode, highlighted
the pro-thrombotic effects of arrhythmia, also affecting platelets and
their participation in this process. All of these results indicate that in ad-
dition to plasma coagulation involvement in the AF pathology the cellu-
lar participation in the evolution of this disorder is important.
222 L. Pourtau et al. / International Journal of Cardiology 243 (2017) 216–2225. Limitations
A limitation to this study is the absence of options to study blood
from the atrium of normal donors as controls. Also there is not enough
information about the pathophysiology of other abnormal cardiac ar-
rhythmia, such as Bouveret syndrome, to consider these patients as po-
tential controls. Future studies will focus on platelet signalization
through the PAR-1 receptor to better explain the platelet desensitiza-
tion to TRAP. We will also determine the cellular origin of the MPs.
Finally the mechanisms bringing about the disappearance of TF-
dependent procoagulant MPs in the left atrium remain to be elucidated,
their attachment to the endocardium or other cells/tissues is an intrigu-
ing option to test.
6. Conclusion
Patients with AF showed significant changes in the platelet response
to PAR-1 activation in favor of a desensitization, partially corrected dur-
ing an acute induced episode of AF, suggesting a continuous rebalancing
of platelet function. Equally, the MPs expressing tissue factor found in
the atrium immediately after an acute AF episode can trigger coagula-
tion and may represent a new therapeutic target.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ijcard.2017.03.068.
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